Postoperative Impact Study on Different Pressure Reduction for Hypertensive Cerebral Hemorrhage

  • Zhanjian Fang
Keywords: Hypertension Treatment, Cerebral Hemorrhage, Blood Pressure Control, Acute Phase

Abstract

This study was designed to compare the clinical benefit of administration to patients with acute hypertensive
cerebral bleeding at different blood pressure levels. Analyze and strengthen the impact of clinical effects of
hypertension treatment for patients with different bleeding sites and whether it can reduce SBPV. In order to
explore a more reasonable blood pressure control method, this article selected patients with hypertensive cerebral
hemorrhage treated by a medical university general hospital from October 2018 to April 2019, and collected
complete clinical data from patients. Based on the above conditions, admission to the hospital within 24 hours
after the onset of hypertensive cerebral hemorrhage, when SBP ≥ 140mmHg, immediately given hypertensive
treatment; When SBP ≥ 120mmHg and SBP ≤ 140mmHg, continue to stay in hospital for 4-6h, screening and
adding to the intensive group. When SBP≥140mmHg and SBP≤180mmHg; continue to stay in hospital for 4-6h,
when SBP ≥180mmHg, screened and added to the juxtaposed case. When SBP≥180mmHg or ≤140mmHg,
continue to stay in hospital for 4-6h, screened and added to the control case. Then compare the effects of SBPV
between the three groups on early clinical benefit and compare the early clinical benefits of three different
bleeding sites (such as basal ganglia, thalamus, lung lobe, and subcolumn). The results show that: (1)
Hypertension treatment is beneficial to the recovery of basal ganglia defects in nervous system diseases and
reduces bleeding of thalamus. (2) On the day of hospitalization, lowering blood pressure treatment can reduce the
risk of lung infection; it may also increase serum creatinine and urea, but still exists in the normal range. (3)
Lowering blood pressure treatment can reduce acute stage SBPV. (4) Lowering blood pressure treatment cannot
improve the quality of life and reduce long-term mortality.

Published
2019-09-15